Metabolic Therapy for Lipedema: Can Tirzepatide Overcome the Treatment Gap?

Abstract

Aims: This article reviews the pathophysiological mechanisms of lipedema and explores the potential benefits of tirzepatide as a novel therapeutic approach. Study Design: Opinion article. Place and Duration of Study: Brazil, January–February 2025. Methodology: A critical analysis of current literature on lipedema pathophysiology and tirzepatide's pharmacological effects, integrating evidence from metabolic, immunological, and fibrotic pathways. Results: Lipedema is a chronic disorder of adipose tissue characterized by disproportionate fat accumulation, inflammation, and fibrosis, predominantly affecting women. Evidence suggests that an estrogen imbalance, rather than strict estrogen dependence, contributes to its pathophysiology. Despite its significant impact on quality of life, pharmacological treatment options remain limited, as lipedematous fat is resistant to caloric restriction, appetite-suppressing medications, and even bariatric surgery. Given recent advances in metabolic therapies, tirzepatide—a dual GLP-1 and GIP receptor agonist—has emerged as a promising candidate for lipedema management. Beyond its well-documented effects on weight loss and glycemic control, tirzepatide exhibits anti-inflammatory, antifibrotic, and thermogenic properties that target key mechanisms of lipedema. It modulates macrophage polarization, inhibits fibrosis-promoting pathways, and enhances energy expenditure via UCP1 activation in brown adipose tissue. However, despite its potential benefits, tirzepatide has yet to be formally evaluated for this condition. Conclusion: This article critically appraises the rationale for tirzepatide as a therapeutic option for lipedema, discussing its potential benefits, limitations, and the urgent need for dedicated clinical trials to establish its efficacy and safety in this underserved patient population.